This Article Full Text (OnlineFirst PDF) All Versions of this Article: 1753465809335159v1 3/2/51    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by dal Negro, R. W. Articles by Turco, P. Search for Related Content PubMed PubMed Citation Articles by dal Negro, R. W. Articles by Turco, P. Social Bookmarking                         What's this?

Clinical and pharmacoeconomic profile of COPD patients with FEV1 50–60% predicted: pilot study on the impact of the extended indication of ICS/LABA

¹ Studi Nazionale di Farmaco-Economia e Farmaco-Epidemiologia, Respiratoria, Verona, Italy; and
² CESFAR, Centro Studi Nazionale di Farmaco-Epidemiologia Respiratoria
³ Division of Pneumology
⁴ CESFAR, Centro Studi

^* To whom correspondence should be addressed. E-mail: rdalnegro{at}ulss22.ven.it.

	Abstract

Background: The use of inhaled corticosteroids (ICS) and long-acting ₂ adrenergics (LABA) in fixed combination (ICS/LABA) was recently extended to COPD patients with a baseline FEV₁ 50–60% predicted, thus broadening the original guideline indications (GOLD 2006) that limited their use only to stages III and IV. Method: The present study was carried out to assess the clinical profile of this new subset of patients, with a view to providing data for future studies on the impact of this novel extension of ICS/LABA use in COPD. Results: Data from the present observational cross-sectional study suggest that COPD patients with FEV₁ 50–60% predicted depict a dichotomic condition: actually, even though resembling milder patients in terms of frequency and severity of their respiratory symptoms, they are much more similar to severer patients in terms of rate of hospital admissions and resource consumption (p < 0.01). In other words, this subset of patients seems to represent a peculiar condition in the evolutional phase of COPD during which therapeutic treatment should be intensified in order to slow down the disease progression effectively. Nevertheless, independently of the severity, the general therapeutic approach to COPD was found to be greatly inadequate when compared to GOLD guidelines, particularly in terms of appropriateness. Conclusions: These findings should pave the way for future studies aimed to long-term monitoring of main outcomes and to evaluate the overall impact of earlier ICS/LABA use on disease progression and lung function decline in COPD.

First published on May 14, 2009, doi:10.1177/1753465809335159

Therapeutic Advances in Respiratory Disease 2009;3:51.

A more recent version of this article appeared on April 1, 2009


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?